1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Hematological and renal toxicity in mice after three cycles of high activity [177Lu]Lu-PSMA-617 with or without human α1-microglobulin
(
- Contribution to journal › Article
- 2023
-
Mark
Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [177Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer
(
- Contribution to journal › Article
-
Mark
Quantitative In Vivo Imaging of the Androgen Receptor Axis Reveals Degree of Prostate Cancer Radiotherapy Response
(
- Contribution to journal › Article
- 2022
-
Mark
Hematological Toxicity in Mice after High Activity Injections of 177Lu-PSMA-617
(
- Contribution to journal › Article
- 2021
-
Mark
A conjugation strategy to modulate antigen binding and FcRn interaction leads to improved tumor targeting and radioimmunotherapy efficacy with an antibody targeting prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
PSA-Targeted Alpha-, Beta-, and Positron-emitting immunotheranostics in murine prostate cancer models and nonhuman primates
(
- Contribution to journal › Article
-
Mark
177Lu-PSMA-617 Therapy in Mice, with or without the Antioxidant α1-Microglobulin (A1M), Including Kidney Damage Assessment Using 99mTc-MAG3 Imaging
(
- Contribution to journal › Article
- 2020
-
Mark
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting
(
- Contribution to journal › Article
- 2014
-
Mark
Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule
(
- Contribution to journal › Article
-
Mark
188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors : preclinical assessment
2014) In Journal of nuclear medicine : official publication, Society of Nuclear Medicine 55(11). p.8-1842(
- Contribution to journal › Article